Abstract
In the past decades, the incidence of cancer keeps its rapid increasing step all over the world and cancer is always an important threat to public health. It is believed that cancer is resulted from a series of genetic alterations leading to progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death, and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predicator of drug and therapy responses, or indeed as target for novel gene therapy is recently patented and very promising. In this review, we have summarized the studies investigating the association between XRCC4, one of the NHEJ genes, and the susceptibility to multiple cancers, and discussed its role in carcinogenesis and application in anticancer drug discovery.
Keywords: XRCC4, polymorphism, cancer, carcinogenesis
Recent Patents on Anti-Cancer Drug Discovery
Title: The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Volume: 3 Issue: 3
Author(s): Cheng-Nan Wu, Shiu-Yun Liang, Chia-Wen Tsai and Da-Tian Bau
Affiliation:
Keywords: XRCC4, polymorphism, cancer, carcinogenesis
Abstract: In the past decades, the incidence of cancer keeps its rapid increasing step all over the world and cancer is always an important threat to public health. It is believed that cancer is resulted from a series of genetic alterations leading to progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death, and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predicator of drug and therapy responses, or indeed as target for novel gene therapy is recently patented and very promising. In this review, we have summarized the studies investigating the association between XRCC4, one of the NHEJ genes, and the susceptibility to multiple cancers, and discussed its role in carcinogenesis and application in anticancer drug discovery.
Export Options
About this article
Cite this article as:
Wu Cheng-Nan, Liang Shiu-Yun, Tsai Chia-Wen and Bau Da-Tian, The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242304
DOI https://dx.doi.org/10.2174/157489208786242304 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-aspirin Non-steroidal Anti-inflammatory Drugs for the Primary Chemoprevention of Non-gastrointestinal Cancer: Summary of Evidence
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology Fluorescence Detection of MMP-9. II. Ratiometric FRET-Based Sensing With Dually Labeled Specific Peptide
Current Pharmaceutical Biotechnology A Systematic Review of the Uterine Relaxant Effect of Herbal Sources
Current Pharmaceutical Biotechnology Physical Activity and Urinary Incontinence in Older Adults: A Community-Based Study
Current Aging Science Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Spectral Perspective on the Electromagnetic Activity of Cells
Current Topics in Medicinal Chemistry The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery MR Imaging Findings of Uterine Cervical Carcinoma
Current Medical Imaging Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets